

VANM243.1APC1



#7

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Gabant, et al.	) Group Art Unit Unknown
App. No.	:	10/031,021	)
Filed	:	January 14, 2002	)
For	:	NON-HUMAN GENETICALLY MODIFIED MAMMAL LACKING THE ALPHA- FETOPROTEIN	)
Examiner	:	Unknown	)

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing twelve (12) references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 4, 2002

By: Daniel Hart  
Daniel Hart  
Registration No. 40,637  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(619) 235-8550

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  O P E J C 1 0 5 APR 12 2002 P A T E N T & T R A D E M A R K O F F I C E	ATTY. DOCKET NO. VANM243.1APC1	APPLICATION NO. 10/031,021  #7
		APPLICANT Gabant, et al.	
		FILING DATE January 14, 2002	GROUP Unknown

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES      NO
1		WO 96/22787	08/01/96	PCT			
2		WO 00/40693	07/13/00	PCT			
3		WO 00/53759	09/14/00	PCT			


EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
4	Jin, et al. (1998) $\alpha$ -Fetoprotein gene sequences mediating <i>Afr2</i> regulation during liver regeneration. Proc. Natl. Acad. Sci. USA, 95:8767-8772	
5	Cirillo, et al. (1995) Developmental Regulation of $\alpha$ -Fetoprotein Expression in Intestinal Epithelial Cells of Transgenic Mice. Developmental Biology 168:395-405	
6	Tyner, et al. (1990) The Ontogeny of $\alpha$ -fetoprotein Gene Expression in the Mouse Gastrointestinal Tract. J. Cell Biology 110:915-927	
7	Millonig, et al. (1995) Molecular Analysis of the Distal Enhancer of the Mouse $\alpha$ -Fetoprotein Gene. Molecular and Cellular Biology p.3848-3856	
8	Chen, et al. (1999) Identification of a Cis-Acting Element in the Rat $\alpha$ -Fetoprotein Gene and its Specific Binding proteins in F9 cells During Retinoic Acid-Induced Differentiation. J. Cellular Biochemistry 72:25-34	
9	Butterfield, et al. (1999) Generation of Human T-cell Responses to an HLA-A2.1-restricted Peptide Epitope Derived from $\alpha$ -Fetoprotein. Cancer Research 59:3134-3142	
10	Henriette, et al. (1997) Negative Regulation of the $\alpha$ -Fetoprotein Gene in Fibroblasts: Identification and Characterization of <i>cis</i> and <i>trans</i> Elements. Folia Biologica (Praga) 43:5-13	
11	Young, et al. (1982) Construction and Expression in vivo of an Internally Deleted mouse $\alpha$ -Fetoprotein gene: Presence of a Transcribed Alu-like repeat within the First Intervening Sequence. Nucleic Acids Research 10:3099-3116	
12	Scohy, et al. (2000) Identification of an Enhancer and an Alternative Promoter in the First Intron of the $\alpha$ -Fetoprotein gene. Nucleic Acids Research 28(19)3743-3751	

O:\DOCS\MCM\MCM-2025.DOC  
040402sev

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Case Docket No. VANM243.IAPCI

Date: April 8, 2002



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :	Gabant, et al.	)	I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on
Appl. No. :	10/031,021	)	
Filed :	January 14, 2002	)	
For :	NON-HUMAN GENETICALLY MODIFIED MAMMAL LACKING THE ALPHA- FETOPROTEIN	)	
Examiner :	Unknown	)	
Group Art Unit :	Unknown	)	

April 8, 2002

(Date)

Daniel Hart

Daniel Hart, Reg. No. 40,637

## TRANSMITTAL LETTER

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

## ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with twelve (12) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Daniel Hart  
Daniel Hart  
Registration No. 40,637  
Attorney of Record